Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Total 13F shares
-
17,661,042
-
Share change
-
-337,509
-
Total reported value
-
$358,518,075
-
Price per share
-
$20.30
-
Number of holders
-
46
-
Value change
-
-$11,587,017
-
Number of buys
-
20
-
Number of sells
-
22
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q1 2021
As of 31 Mar 2021,
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,661,042 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO, FRANKLIN RESOURCES INC, Artal Group S.A., Casdin Capital, LLC, SANDS CAPITAL MANAGEMENT, LLC, Alphabet Inc., TYBOURNE CAPITAL MANAGEMENT (HK) LTD, and PERCEPTIVE ADVISORS LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.